About elafibranor
PPAR alpha/delta agonist
Used for
- Treats primary biliary cholangitis (PBC) with ursodeoxycholic acid when response is inadequate.
- May be used alone when ursodeoxycholic acid cannot be tolerated.
Usual adult dose
80 mg by mouth once daily, with or without food.
Common side effects
- Abdominal pain
- Diarrhea
- Nausea
- Muscle pain
Important warnings
- Monitor for muscle injury, especially with statins or unexplained muscle symptoms.
- Assess for fractures; bone fractures have occurred during treatment.
- Liver tests may worsen; monitor liver function and stop if serious liver injury is suspected.
- Not recommended for decompensated cirrhosis; effectiveness is not established for preventing liver failure or death.
Pregnancy
May cause fetal harm based on animal studies; human pregnancy data are limited.
Breastfeeding
Unknown whether elafibranor enters breast milk; consider benefits of breastfeeding and treatment.
Interactions
- Bile acid sequestrants can reduce absorption; take elafibranor at least 4 hours before or after them.
- May increase exposure to statins and other medicines affected by transport proteins; monitor for adverse effects.
- Cyclosporine may increase elafibranor exposure; monitor for side effects.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.